Results 161 to 170 of about 258,109 (297)

Retrospective Analysis of Inflammatory Parameters and Vitamins' Levels in Psoriasis Patients: A Case-Control Study. [PDF]

J Inflamm Res
Murshidi R, Bani Hamad S, Al Refaei A, Shewaikani N, Al-Nusair DA, Abu Tawileh HB, Murshidi M, Alzeerelhouseini HIA.   +7 more
europepmc   +1 more source

Successful Use of Bimekizumab in Refractory Acute Generalised Exanthematous Pustulosis Triggered by Amoxicillin‐Clavulanate

JEADV Clinical Practice, EarlyView.
ABSTRACT Acute generalised exanthematous pustulosis (AGEP) is a rare, acute neutrophilic dermatosis most commonly triggered by drugs, which typically resolves within 2 weeks following withdrawal of the causative agent. Topical and systemic corticosteroids remain the standard treatment.
Alexandra Junge, Charlotte Vogel, Theresa Hempel, Basil Signer, Nikhil Yawalkar, Kristine Heidemeyer   +5 more
wiley   +1 more source

Systemic Inflammatory Indexes as Easy-to-Use Markers for Monitoring Psoriasis and Hidradenitis Suppurativa. [PDF]

Acta Derm Venereol
Di Brizzi EV, Buononato D, Falco AL, Fulgione E, Caccavale S, Argenziano G, Balato A.   +6 more
europepmc   +1 more source

Cutaneous and mucosal manifestations associated with celiac disease [PDF]

, 2018
Beteta Gorriti, Valia Patricia, Dios Velázquez, Álvaro de, Gómez de Castro, Celia, Palacios García, Laura, Rodrigo Sáez, Luis Ricardo, Santos-Juanes Jiménez, Jorge, Álvarez, Nuria   +6 more
core   +2 more sources

Characteristics and Clinical Outcomes of Patients With Hidradenitis Suppurativa (HS) Treated With Bimekizumab: A Canadian Retrospective Chart Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterised by painful nodules, abscesses, and draining and non‐draining tunnels. Currently, there are two biologics approved in Canada for the treatment of moderate‐to‐severe HS, adalimumab (anti‐TNF) and secukinumab (anti‐IL‐17A).
Irina Turchin, Tracey Brown‐Maher, Hélène Veillette, David O. Croitoru, Kyle Cullingham   +4 more
wiley   +1 more source

Identification and clinical implications of immune-related hub genes in psoriasis. [PDF]

PLoS One
Sun Y, Zhou Z, Mao Y, Liu N, Li Y, Fang W.   +5 more
europepmc   +1 more source

Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

JEADV Clinical Practice, EarlyView.
ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson, Kara Hurley, Hannah Chaudhury, Lara Shehadeh, Cameron West   +4 more
wiley   +1 more source

The Effectiveness of Probiotics in Psoriasis: An Umbrella Review. [PDF]

J Nutr Metab
Ayuningtyas M, Farapti F, Hajar SS.
europepmc   +1 more source

Application of Trichoscopy and Novel Non-Invasive Imaging Techniques in the Diagnosis and Management of Patients with Scalp Psoriasis. [PDF]

Psoriasis (Auckl)
Kuchnicka A, Fałkowska U, Konopelski P, Anderson A, Rakowska A, Kurzeja M, Olszewska M, Rudnicka L.   +7 more
europepmc   +1 more source

Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‑1 RAs) play a pivotal role in treating type 2 diabetes. Despite their widespread use, their dermatological manifestations remain under‐recognized, hence the interest of this systematic review. Objectives This systematic review aims to assess dermatological manifestations associated with
Nour Ghostine, Maya Halabi‐Tawil
wiley   +1 more source